BIOSENSE WEBSTER, INC.

Johnson & Johnson MedTech Reports Promising 3-Month Data for OMNYPULSE Platform in Atrial Fibrillation Treatment

a month ago

• The investigational OMNYPULSE Platform demonstrated 100% acute success and 84.5% pulmonary vein isolation durability at three months in patients with paroxysmal atrial fibrillation, with only a 3.0% primary adverse event rate. • Additional data from the VARIPURE registry showed strong safety outcomes with no serious adverse events reported across 247 patients and minimal learning curve for new operators, suggesting potential for broader clinical adoption. • Johnson & Johnson MedTech also presented preclinical validation of the Pulsed Field Index from their Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, accurately predicting lesion depth within ±1mm in 92% of cases.

Johnson & Johnson MedTech's Dual-Energy Catheter Receives CE Mark for Cardiac Arrhythmia Treatment

4 months ago

• Johnson & Johnson MedTech's Dual Energy THERMOCOOL SMARTTOUCH SF Catheter has received European CE Mark approval for treating cardiac arrhythmias. • The catheter allows electrophysiologists to switch between radiofrequency (RF) and pulsed field (PF) energy during ablation procedures. • Clinical trial results showed a 100% acute success rate and 96.8% first-pass isolation in treating paroxysmal atrial fibrillation (AFib). • Studies are underway in the US, Australia, and Canada to expand the availability of the dual-energy catheter.